BACKGROUND: The t(14;18) translocation is a common finding in nodal follicular B cell lymphomas and diffuse large B cell lymphomas, and results in the overexpression of the antiapoptotic bcl2 protein. This chromosome rearrangement can be detected by the polymerase chain reaction (PCR), with most breakpoints in the bcl2 gene occurring within either the major breakpoint region (mbr) or the minor cluster region (mcr). However, recent investigations have revealed several breakpoints between these two regions, which cluster 19 kb 3' of mbr in the "intermediate cluster region" (icr). AIMS/ METHODS: To analyse a series of 57 B cell follicular lymphomas known to carry the t(14;18) by PCR with primers directed against all three cluster regions to determine the efficacy of screening the icr site. RESULTS: Twenty six samples had an mbr rearrangement, four an mcr rearrangement, and three an icr rearrangement. CONCLUSIONS: These results suggest that screening for icr is at least as efficacious as screening for mcr rearrangements.
BACKGROUND: The t(14;18) translocation is a common finding in nodal follicular B cell lymphomas and diffuse large B cell lymphomas, and results in the overexpression of the antiapoptotic bcl2 protein. This chromosome rearrangement can be detected by the polymerase chain reaction (PCR), with most breakpoints in the bcl2 gene occurring within either the major breakpoint region (mbr) or the minor cluster region (mcr). However, recent investigations have revealed several breakpoints between these two regions, which cluster 19 kb 3' of mbr in the "intermediate cluster region" (icr). AIMS/ METHODS: To analyse a series of 57 B cell follicular lymphomas known to carry the t(14;18) by PCR with primers directed against all three cluster regions to determine the efficacy of screening the icr site. RESULTS: Twenty six samples had an mbr rearrangement, four an mcr rearrangement, and three an icr rearrangement. CONCLUSIONS: These results suggest that screening for icr is at least as efficacious as screening for mcr rearrangements.
Authors: Andrea Albinger-Hegyi; Bernhard Hochreutener; Marie-Therese Abdou; Ivan Hegyi; María Teresa Dours-Zimmermann; Michael O Kurrer; Philipp U Heitz; Dieter R Zimmermann Journal: Am J Pathol Date: 2002-03 Impact factor: 4.307
Authors: J J M van Dongen; A W Langerak; M Brüggemann; P A S Evans; M Hummel; F L Lavender; E Delabesse; F Davi; E Schuuring; R García-Sanz; J H J M van Krieken; J Droese; D González; C Bastard; H E White; M Spaargaren; M González; A Parreira; J L Smith; G J Morgan; M Kneba; E A Macintyre Journal: Leukemia Date: 2003-12 Impact factor: 11.528
Authors: Hakim Bouamar; Saman Abbas; An-Ping Lin; Long Wang; Daifeng Jiang; Kenneth N Holder; Marsha C Kinney; Scott Hunicke-Smith; Ricardo C T Aguiar Journal: Blood Date: 2013-06-17 Impact factor: 22.113
Authors: Olga K Weinberg; Weiyun Z Ai; M Rajan Mariappan; Carol Shum; Ronald Levy; Daniel A Arber Journal: J Mol Diagn Date: 2007-07-25 Impact factor: 5.568
Authors: Alyssa Bouska; Timothy W McKeithan; Karen E Deffenbacher; Cynthia Lachel; George W Wright; Javeed Iqbal; Lynette M Smith; Weiwei Zhang; Can Kucuk; Andrea Rinaldi; Francesco Bertoni; Jude Fitzgibbon; Kai Fu; Dennis D Weisenburger; Timothy C Greiner; Bhavana J Dave; Randy D Gascoyne; Andreas Rosenwald; German Ott; Elias Campo; Lisa M Rimsza; Jan Delabie; Elaine S Jaffe; Rita M Braziel; Joseph M Connors; Louis M Staudt; Wing-Chung Chan Journal: Blood Date: 2013-09-13 Impact factor: 22.113